These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 37266989)

  • 1. Comparison table: Some drugs for migraine prevention in adults.
    Med Lett Drugs Ther; 2023 Jun; 65(1678):e100-e102. PubMed ID: 37266989
    [No Abstract]   [Full Text] [Related]  

  • 2. Drugs for migraine.
    Med Lett Drugs Ther; 2023 Jun; 65(1678):89-96. PubMed ID: 37266987
    [No Abstract]   [Full Text] [Related]  

  • 3. Eptinezumab (Vyepti) for migraine prevention.
    Med Lett Drugs Ther; 2020 Jun; 62(1599):85-87. PubMed ID: 32555116
    [No Abstract]   [Full Text] [Related]  

  • 4. Atogepant (Qulipta) for migraine prevention.
    Med Lett Drugs Ther; 2021 Nov; 63(1636):169-171. PubMed ID: 35085204
    [No Abstract]   [Full Text] [Related]  

  • 5. Fremanezumab (Ajovy) and galcanezumab (Emgality) for migraine prevention.
    Med Lett Drugs Ther; 2018 Nov; 60(1559):177-180. PubMed ID: 30681655
    [No Abstract]   [Full Text] [Related]  

  • 6. Drugs for Migraine.
    Med Lett Drugs Ther; 2020 Oct; 62(1608):153-160. PubMed ID: 33434187
    [No Abstract]   [Full Text] [Related]  

  • 7. Erenumab (Aimovig) for migraine prevention.
    Med Lett Drugs Ther; 2018 Jun; 60(1549):101-103. PubMed ID: 29913472
    [No Abstract]   [Full Text] [Related]  

  • 8. Zavegepant (Zavzpret) for acute treatment of migraine.
    Med Lett Drugs Ther; 2023 Jul; 65(1681):116-118. PubMed ID: 37460143
    [No Abstract]   [Full Text] [Related]  

  • 9. Rimegepant (Nurtec ODT) for acute treatment of migraine.
    Med Lett Drugs Ther; 2020 May; 62(1597):70-72. PubMed ID: 32555113
    [No Abstract]   [Full Text] [Related]  

  • 10. In brief: Hypertension with erenumab (Aimovig).
    Med Lett Drugs Ther; 2021 Apr; 63(1621):56. PubMed ID: 33830970
    [No Abstract]   [Full Text] [Related]  

  • 11. In brief: Erenumab (Aimovig) hypersensitivity.
    Med Lett Drugs Ther; 2019 Mar; 61(1568):48. PubMed ID: 31022159
    [No Abstract]   [Full Text] [Related]  

  • 12. Migraine therapeutics differentially modulate the CGRP pathway.
    Bhakta M; Vuong T; Taura T; Wilson DS; Stratton JR; Mackenzie KD
    Cephalalgia; 2021 Apr; 41(5):499-514. PubMed ID: 33626922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.
    Berman G; Croop R; Kudrow D; Halverson P; Lovegren M; Thiry AC; Conway CM; Coric V; Lipton RB
    Headache; 2020 Sep; 60(8):1734-1742. PubMed ID: 32799325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of galcanezumab in patients with migraine who did not benefit from commonly prescribed preventive treatments.
    Kuruppu DK; Tobin J; Dong Y; Aurora SK; Yunes-Medina L; Green AL
    BMC Neurol; 2021 Apr; 21(1):175. PubMed ID: 33892641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Network meta-analysis on efficacy and safety of different anti-CGRP monoclonal antibody regimens for prophylaxis and treatment of episodic migraine.
    Shi M; Guo J; Li Z; Sun H; Yang X; Yang D; Zhao H
    Neurol Res; 2021 Nov; 43(11):932-949. PubMed ID: 34281473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of erenumab for migraine prophylaxis during pregnancy: A case report and narrative review.
    Vig SJ; Garza J; Tao Y
    Headache; 2022 Nov; 62(10):1256-1263. PubMed ID: 35467013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Matching-adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health-related quality of life in the treatment of migraine.
    Popoff E; Johnston K; Croop R; Thiry A; Harris L; Powell L; Coric V; L'Italien G; Moren J
    Headache; 2021 Jun; 61(6):906-915. PubMed ID: 34021585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: A systematic review and network meta-analysis.
    Messina R; Huessler EM; Puledda F; Haghdoost F; Lebedeva ER; Diener HC
    Cephalalgia; 2023 Mar; 43(3):3331024231152169. PubMed ID: 36786548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medications for migraine prophylaxis.
    Modi S; Lowder DM
    Am Fam Physician; 2006 Jan; 73(1):72-8. PubMed ID: 16417067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost of fremanezumab, erenumab, galcanezumab and onabotulinumtoxinA associated adverse events, for migraine prophylaxis in Spain.
    Irimia P; Santos-Lasaosa S; García Bujalance L; Ramos Pinazo L; Rubio-Rodríguez D; Rubio-Terrés C
    Expert Rev Pharmacoecon Outcomes Res; 2021 Apr; 21(2):285-297. PubMed ID: 32484365
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.